SCHEMBL30108049

SCHEMBL30108049

Nc1nc(-c2ccco2)cc(-n2c(-c3ccncc3)nc3ccccc32)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
ADORA2A P29274 6/20 0.42
ADORA1 P30542 5/20 0.42
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 5/20 0.42
KDM4E B2RXH2 4/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 2/20 0.40
TP53 P04637 1/20 0.40
ADORA2B P29275 3/20 0.39
USP2 O75604 1/20 0.39
ADORA3 P0DMS8 2/20 0.38
LMNA P02545 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30107952 0.88 ADORA2A (0.41) TSHRNPC1HTTRAB9AADORA2A
SCHEMBL30108043 0.85 ADORA2A (0.41) HTTRAB9AADORA2AADORA1ALDH1A1
SCHEMBL30107942 0.83 ADORA2A (0.47) TSHRNPC1HTTRAB9AADORA2A
SCHEMBL30108022 0.77 SLC6A2 (0.37) ADORA2AADORA1
SCHEMBL30108012 0.73 TSHR (0.58) TSHRNPC1HTTRAB9AADORA2A
SCHEMBL30107964 0.72 ADORA2A (0.46) ADORA2AADORA1ADORA2BADORA3
SCHEMBL30108063 0.72 KDM4E (0.40) TSHRNPC1HTTRAB9AADORA2A
SCHEMBL1554000 0.69 MAPT (0.58) ADORA2AADORA1ALDH1A1HSD17B10KDM4E
SCHEMBL12116702 0.67 ESR2 (0.65) HTTALDH1A1HSD17B10KDM4EMAPK1
SCHEMBL5017647 0.66 SMN1; SMN2 (0.54) TSHRNPC1RAB9AADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022203399-A1 ADENOSINE A2A RECEPTOR ANTAGONIST AND USE THEREOF 주식회사 스탠다임 2022-09-29 WO disclosed